Shares of Safeguard Scientifics, Inc (NYSE:SFE) have been given an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.

Analysts have set a twelve-month consensus price objective of $17.00 for the company and are expecting that the company will post ($0.94) EPS for the current quarter, according to Zacks. Zacks has also assigned Safeguard Scientifics an industry rank of 166 out of 256 based on the ratings given to its competitors.

Separately, Zacks Investment Research cut shares of Safeguard Scientifics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th.

NYSE SFE traded up $0.14 on Friday, reaching $9.78. The company had a trading volume of 1,646 shares, compared to its average volume of 101,090. The company has a market capitalization of $198.42 million, a price-to-earnings ratio of -2.21 and a beta of 1.00. Safeguard Scientifics has a fifty-two week low of $7.98 and a fifty-two week high of $13.95. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.76.

Safeguard Scientifics (NYSE:SFE) last posted its quarterly earnings data on Thursday, October 25th. The asset manager reported $1.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.61 by ($0.05). Research analysts expect that Safeguard Scientifics will post -0.89 earnings per share for the current fiscal year.

In related news, CFO Mark Herndon acquired 10,000 shares of the business’s stock in a transaction dated Friday, December 7th. The shares were bought at an average price of $9.44 per share, with a total value of $94,400.00. Following the transaction, the chief financial officer now directly owns 28,000 shares of the company’s stock, valued at $264,320. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Ira M. Lubert sold 6,066 shares of the stock in a transaction dated Friday, December 14th. The stock was sold at an average price of $9.15, for a total transaction of $55,503.90. The disclosure for this sale can be found here. Insiders have acquired 16,400 shares of company stock worth $153,935 in the last ninety days. Insiders own 2.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Mycio Wealth Partners LLC lifted its position in Safeguard Scientifics by 43.0% in the 3rd quarter. Mycio Wealth Partners LLC now owns 33,241 shares of the asset manager’s stock valued at $311,000 after acquiring an additional 10,000 shares in the last quarter. Prudential Financial Inc. lifted its position in Safeguard Scientifics by 23.9% in the 3rd quarter. Prudential Financial Inc. now owns 53,361 shares of the asset manager’s stock valued at $499,000 after acquiring an additional 10,300 shares in the last quarter. Legal & General Group Plc lifted its position in Safeguard Scientifics by 13.8% in the 2nd quarter. Legal & General Group Plc now owns 87,683 shares of the asset manager’s stock valued at $1,122,000 after acquiring an additional 10,639 shares in the last quarter. SG Americas Securities LLC bought a new position in Safeguard Scientifics in the 2nd quarter valued at about $141,000. Finally, First Manhattan Co. lifted its position in Safeguard Scientifics by 0.7% in the 3rd quarter. First Manhattan Co. now owns 1,575,296 shares of the asset manager’s stock valued at $14,729,000 after acquiring an additional 11,079 shares in the last quarter. 72.04% of the stock is currently owned by institutional investors.

About Safeguard Scientifics

Safeguard Scientifics, Inc no longer investing. It is a private equity and venture capital firm specializing in expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, growth stage, and early stage financings. It initially invests in a Series A-C round and opportunistically in a seed round.

See Also: Discount Rate

Get a free copy of the Zacks research report on Safeguard Scientifics (SFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Safeguard Scientifics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Safeguard Scientifics and related companies with MarketBeat.com's FREE daily email newsletter.